Covered recipient · General Payments record
HAYLEY M LEIGHT-DUNN
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$1,674.15
- Reported across 51 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $431.67 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $256.69 | 9 |
| GENZYME CORPORATION | $50.77 | 2 |
| Lilly USA, LLC | $31.08 | 2 |
| E.R. Squibb & Sons, L.L.C. | $28.69 | 1 |
| REVANCE THERAPEUTICS, INC. | $28.18 | 1 |
| Amgen Inc. | $18.34 | 1 |
| Galderma Laboratories, L.P. | $17.92 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $31.22 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104159416 | CMS |
| ABBVIE INC. | $107.10 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104159418 | CMS |
| ABBVIE INC. | $24.38 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104159420 | CMS |
| ABBVIE INC. | $16.62 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104159422 | CMS |
| ABBVIE INC. | $17.57 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104159424 | CMS |
| ABBVIE INC. | $16.92 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104159426 | CMS |
| ABBVIE INC. | $12.68 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104159428 | CMS |
| ABBVIE INC. | $4.90 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104159430 | CMS |
| ABBVIE INC. | $25.30 | 11/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104159432 | CMS |
| Amgen Inc. | $18.34 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117308717 | CMS |
| E.R. Squibb & Sons, L.L.C. | $28.69 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101657436 | CMS |
| Galderma Laboratories, L.P. | $17.92 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145312248 | CMS |
| GENZYME CORPORATION | $19.37 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140001441 | CMS |
| GENZYME CORPORATION | $31.40 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140001453 | CMS |
| Lilly USA, LLC | $13.64 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135016160 | CMS |
| Lilly USA, LLC | $17.44 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135016158 | CMS |
| REVANCE THERAPEUTICS, INC. | $28.18 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147922862 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.